PriceTargets.com logo

NYSE:VOR - Vor Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.71
  • Forecasted Upside: 533.04 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.22 As of 05/18/2022 01:00 AM ET
▼ -0.07 (-1.63%)

This chart shows the closing price for VOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vor Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VOR

Analyst Price Target is $26.71
▲ +533.04% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $26.71, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 533.04% upside from the last price of $4.22.

This chart shows the closing price for VOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Vor Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2022HC WainwrightReiterated RatingBuy$26.00Medium
5/13/2022JMP SecuritiesLower Price Target$30.00 ➝ $15.00High
4/27/2022The Goldman Sachs GroupInitiated CoverageNeutral$6.00Low
3/21/2022BarclaysLower Price TargetOverweight$56.00 ➝ $26.00High
3/16/2022JMP SecuritiesLower Price TargetBuy$40.00 ➝ $30.00High
3/15/2022HC WainwrightReiterated RatingBuy$26.00Low
1/24/2022B. RileyLower Price Target$60.00 ➝ $46.00High
12/17/2021HC WainwrightInitiated CoverageBuy$26.00High
12/2/2021Robert W. BairdInitiated CoverageOutperform$38.00High
12/1/2021OppenheimerInitiated CoverageOutperform$30.00High
10/19/2021JMP SecuritiesInitiated CoverageOutperform$40.00High
5/7/2021B. RileyReiterated RatingBuy$60.00High
3/24/2021B. RileyInitiated CoverageBuy$60.00Low
3/3/2021BarclaysInitiated CoverageOverweight$56.00High
3/2/2021Evercore ISIInitiated CoverageOutperform$48.00High
3/2/2021Stifel NicolausInitiated CoverageBuy$58.00High
3/2/2021The Goldman Sachs GroupInitiated CoverageSell$19.00High
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2022

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Vor Biopharma logo
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.22
Low: $4.13
High: $4.33

50 Day Range

MA: $6.08
Low: $4.01
High: $8.51

52 Week Range

Now: $4.22
Low: $4.01
High: $23.79

Volume

90,544 shs

Average Volume

96,082 shs

Market Capitalization

$158.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vor Biopharma?

The following Wall Street research analysts have issued research reports on Vor Biopharma in the last year: B. Riley, Barclays PLC, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Robert W. Baird, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for VOR.

What is the current price target for Vor Biopharma?

0 Wall Street analysts have set twelve-month price targets for Vor Biopharma in the last year. Their average twelve-month price target is $26.71, suggesting a possible upside of 533.0%.
View the latest price targets for VOR.

What is the current consensus analyst rating for Vor Biopharma?

Vor Biopharma currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VOR will outperform the market and that investors should add to their positions of Vor Biopharma.
View the latest ratings for VOR.

How do I contact Vor Biopharma's investor relations team?

The company's listed phone number is 617 655 6580. The official website for Vor Biopharma is www.vorbiopharma.com. Learn More about contacing Vor Biopharma investor relations.